SHR3680 + digoxin + rosuvastatin

This is a **combination of three drugs**: - **SHR3680 (rezvilutamide)**: a novel, small molecule androgen receptor antagonist developed for the treatment of prostate cancer. It acts by inhibiting androgen receptor nuclear translocation and transcriptional activity, preventing androgen-driven tumor cell proliferation[1][3][5][7]. - **Digoxin**: a cardiac glycoside used for treating heart failure and certain arrhythmias, inhibiting sodium/potassium ATPase, increasing intracellular calcium, thus enhancing cardiac contractility. - **Rosuvastatin**: a synthetic statin (HMG-CoA reductase inhibitor) used to lower cholesterol and prevent cardiovascular disease by inhibiting hepatic cholesterol production, resulting in decreased LDL and triglycerides and increased HDL[2][4][6][8]. No approved fixed-dose combination exists of these three agents; any such combination would be for investigational or off-label clinical pharmacology studies, for example, to assess drug-drug interactions.

Other names

rezvilutamiderosuvastatin